The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery
Pharmaceutics · 12.11.2023 · 15 (11) · 2619
DOI: 10.3390/pharmaceutics15112619 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 12.11.2023. Verfasst von Hiroshi Komura und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Research Administration Center, Osaka Metropolitan University, 1-2-7 Asahimachi, Abeno-ku, Osaka 545-0051, Osaka, Japan. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Drug discovery and development are aimed at identifying new chemical molecular entities (NCEs) with desirable pharmacokinetic profiles for high therapeutic efficacy. The plasma concentrations of NCEs are a biomarker of their efficacy and are governed by pharmacokinetic processes such as absorption, distribution, metabolism, and excretion (ADME). Poor ADME properties of NCEs are a major cause of attrition in drug development. ADME screening is used to identify and optimize lead compounds in the drug discovery process. Computational models predicting ADME properties have been developed with evolving model-building technologies from a simplified relationship between ADME endpoints and physicochemical properties to machine learning, including support vector machines, random forests, and convolution neural networks. Recently, in the field of in silico ADME research, there has been a shift toward evaluating the in vivo parameters or plasma concentrations of NCEs instead of using predictive results to guide chemical structure design. Another research hotspot is the establishment of a computational prediction platform to strengthen academic drug discovery. Bioinformatics projects have produced a series of in silico ADME models using free software and open-access databases. In this review, we introduce prediction models for various ADME parameters and discuss the currently available academic drug discovery platforms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Research Administration Center, Osaka Metropolitan University, 1-2-7 Asahimachi, Abeno-ku, Osaka 545-0051, Osaka, Japan.
- Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita 565-0871, Osaka, Japan.
- Artificial Intelligence Centre for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health, and Nutrition (NIBIOHN), 3-17 Senrioka-shinmachi, Settu 566-0002, Osaka, Japan.
ORCID-Profile: Hiroshi Komura, Reiko Watanabe, Kenji Mizuguchi
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Komura, H., Watanabe, R., & Mizuguchi, K. (2023). The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery. Pharmaceutics, 15(11), 2619. https://doi.org/10.3390/pharmaceutics15112619
Vancouver
Komura H, Watanabe R, Mizuguchi K. The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery. Pharmaceutics. 2023;15(11):2619. doi:10.3390/pharmaceutics15112619
BibTeX
@article{Komura2023,
author = {Komura, Hiroshi and Watanabe, Reiko and Mizuguchi, Kenji},
title = {The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {11},
pages = {2619},
doi = {10.3390/pharmaceutics15112619}
}
EUVIMED